CEACAM5 and medullary thyroid gland carcinoma: Earlier clinical studies reported a high sensitivity of pretargeted immunoscintigraphic using murine or chimeric anticarcinoembryonic antigen (CEA), bispecific antibody (BsMAb), and peptides labeled with 111In or 131I in MTC.